Taconic Biosciences, Inc.

Taconic Biosciences, Inc., a for-profit manufacturer of genetically engineered rodent models and specialized laboratory animals, operates as a prime contractor (100% of awards) supplying live animals, customized transgenic and knockout mouse and rat lines, and breeding facility services to the National Institutes of Health ecosystem and other federal health agencies on full-and-open federal contracts without set-aside designations. The company is headquartered in Germantown, New York, and has served 44 distinct federal customer agencies across 754 total awards since 1988, with $465.6 million in combined potential value and $144.5 million in combined dollars obligated.

Taconic's federal footprint concentrates heavily within the NIH ecosystem. The top five customer entities account for 63% of combined potential value, led by the NIH Office of Logistics and Acquisition Operations (41 awards, $162.7 million), the National Institute of Environmental Health Sciences (55 awards, $59.5 million), and the National Institute of Allergy and Infectious Diseases (19 awards, $46.2 million). The two rankings diverge materially — NIEHS places the highest number of individual task orders but ranks third by dollar value, while OLA&O anchors fewer awards but drives the largest aggregate ceiling. The National Heart Lung and Blood Institute and NIAID's DEA OA Acquisitions unit round out the top-five value customers. Taconic holds a $99 million indefinite-delivery contract with NIH's Office of Logistics and Acquisition Operations through October 2024, which serves as the parent vehicle for much of its NIH work; five named parent vehicles carry 88 combined task orders, with the HHSN273200800009I IDC generating 37 task orders worth $4.1 million.

Recent capability work exemplifies Taconic's core service set. A June 2026 delivery order from NIAID valued at $5.7 million covers operation and maintenance of a murine pathogen-free mouse breeding facility at North Bethesda, Maryland, with firm fixed-price terms and a completion date of December 2026. A June 2025 delivery order for the same facility scope carried $3.4 million and completed June 2026. A June 2023 purchase order from NIAID for operation and maintenance of that same facility ran $7.4 million with a base period through June 2024 and two one-year option periods; government-invoiced labor totaled $456 thousand in FY2023 and $3.5 million in FY2024 on this facility contract. Additional recent work includes a $148 thousand August 2022 purchase order from the National Human Genome Research Institute for generation of transgenic mouse models supporting propionic acidemia and methylmalonic acidemia research, a $625 thousand cost-plus-fixed-fee definitive contract from the National Institute of Environmental Health Sciences for production of B6C3F1/N mice for the National Toxicology Program, and a $57 thousand November 2024 purchase order from Veterans Integrated Service Network 7 for TurboKnockOut mutant mice.

Activity volume has been sparse in the past three years — one award each in 2024, 2025, and 2026 — a sharp decline from six to seven annual awards in 2022 and 2023. The vendor's category footprint is dominated by NAICS All Other Animal Production (300 awards) and PSC Live Animals, Not Raised For Food (398 awards), reflecting its core business as a laboratory-animal supplier. Only two awards face completion within the next twenty-four months, carrying combined potential value of $5.8 million and presenting minimal recompete exposure in that window.

SCI-reportable invoiced revenue totaled $4.8 million across fiscal years 2022 through 2024, with $1.4 million in FY2023 (3.6 FTEs) and $3.5 million in FY2024; SCI data captures federal service contracts above the $150,000 threshold and excludes Taconic's substantial goods and animal-supply revenue, which constitutes the bulk of its federal work. Government-paid hourly rates on SCI-reportable prime contracts ran at a flat median of $120.44 per hour. Taconic operates with zero sub-engagement — all SCI-reportable work is self-performed — and maintains a named subsidiary, Taconic Biosciences Corporation. The company operates exclusively as a prime contractor with no subcontract awards in the source portfolio.